These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12053420)

  • 21. Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective.
    Xie F; Bowen JM; Sutherland SC; Burke N; Blackhouse G; Tarride JE; O'Reilly D; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):513-21. PubMed ID: 21958096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health care technology in Canada (with special reference to Quebec).
    Battista RN; Jacob R; Hodge MJ
    Health Policy; 1994; 30(1-3):73-122. PubMed ID: 10139497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canadian Coordinating Office for Health Technology Assessment.
    Menon D
    CMAJ; 1992 Jan; 146(2):113. PubMed ID: 1735034
    [No Abstract]   [Full Text] [Related]  

  • 24. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
    Fischer KE; Heisser T; Stargardt T
    Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hospital-based technology assessment programmes: two Canadian examples.
    Juzwishin D; Olmstead D; Menon D
    World Hosp Health Serv; 1996; 32(2):2-9. PubMed ID: 10165872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Requirements for and expectations of health technology assessment in Galicia (Spain). A qualitative study from the perspective of decision-makers and clinicians].
    Varela-Lema L; Merino GA; García ML; Martínez MV; Triana EG; Mota TC
    Gac Sanit; 2011; 25(6):454-60. PubMed ID: 21820766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A national technology assessment institute.
    Howell A
    Healthplan; 2003; 44(5):40-5. PubMed ID: 14556611
    [No Abstract]   [Full Text] [Related]  

  • 29. Health technology assessment in Canada. A decade in review.
    Menon D; Topfer LA
    Int J Technol Assess Health Care; 2000; 16(3):896-902. PubMed ID: 11028144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissemination of health technology assessments: identifying the visions guiding an evolving policy innovation in Canada.
    Lehoux P; Denis JL; Tailliez S; Hivon M
    J Health Polit Policy Law; 2005 Aug; 30(4):603-41. PubMed ID: 16318164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health technology assessment in Denmark: strategy, implementation, and developments.
    Sigmund H; Kristensen FB
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():94-101. PubMed ID: 19505351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Selective serotonin reuptake inhibitors for major depression.
    Int J Technol Assess Health Care; 1998; 14(2):394-6. PubMed ID: 9611913
    [No Abstract]   [Full Text] [Related]  

  • 34. HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN EUROPE: PROCESSES, PRACTICES, AND METHODS.
    Fuchs S; Olberg B; Panteli D; Busse R
    Int J Technol Assess Health Care; 2016 Jan; 32(4):246-255. PubMed ID: 27670589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health technology assessment in Germany. Status, challenges, and development.
    Perleth M; Busse R
    Int J Technol Assess Health Care; 2000; 16(2):412-28. PubMed ID: 10932416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Providing information on emerging health technologies to provincial decision makers: a pilot project.
    Hailey D; Topfer LA; Wills F
    Health Policy; 2001 Oct; 58(1):15-26. PubMed ID: 11518599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current technology assessment programs/procedures.
    McDonough R
    J Laparoendosc Surg; 1993 Aug; 3(4):395-7. PubMed ID: 8268513
    [No Abstract]   [Full Text] [Related]  

  • 39. Disinvestment Activities and Candidates in the Health Technology Assessment Community: An Online Survey.
    Polisena J; Trunk G; Gutierrez-Ibarluzea I; Joppi R
    Int J Technol Assess Health Care; 2019 Jan; 35(3):189-194. PubMed ID: 31006390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health technology assessment. The pharmaceutical industry perspective.
    Schubert F
    Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.